194 related articles for article (PubMed ID: 14500340)
1. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
5. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
6. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
7. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
10. Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis.
El-Hashemite N; Walker V; Kwiatkowski DJ
Cancer Res; 2005 Mar; 65(6):2474-81. PubMed ID: 15781664
[TBL] [Abstract][Full Text] [Related]
11. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
Gao X; Zhang Y; Arrazola P; Hino O; Kobayashi T; Yeung RS; Ru B; Pan D
Nat Cell Biol; 2002 Sep; 4(9):699-704. PubMed ID: 12172555
[TBL] [Abstract][Full Text] [Related]
12. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
Lee DF; Kuo HP; Chen CT; Hsu JM; Chou CK; Wei Y; Sun HL; Li LY; Ping B; Huang WC; He X; Hung JY; Lai CC; Ding Q; Su JL; Yang JY; Sahin AA; Hortobagyi GN; Tsai FJ; Tsai CH; Hung MC
Cell; 2007 Aug; 130(3):440-55. PubMed ID: 17693255
[TBL] [Abstract][Full Text] [Related]
13. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.
Jiang X; Yeung RS
Cancer Res; 2006 May; 66(10):5258-69. PubMed ID: 16707451
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.
Nellist M; Burgers PC; van den Ouweland AM; Halley DJ; Luider TM
Biochem Biophys Res Commun; 2005 Aug; 333(3):818-26. PubMed ID: 15963462
[TBL] [Abstract][Full Text] [Related]
16. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.
Kobayashi T; Minowa O; Sugitani Y; Takai S; Mitani H; Kobayashi E; Noda T; Hino O
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8762-7. PubMed ID: 11438694
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
18. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]